Telomere maintenance as a target for anticancer drug discovery.

Nat Rev Drug Discov 2002 May;1(5):383-93

CRC Biomolecular Structure Unit, Chester Beatty Laboratories, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.

Maintenance of telomeres--specialized complexes that protect the ends of chromosomes--is undertaken by the enzyme complex telomerase, which is a key factor that is activated in more than 80% of cancer cells that have been examined so far, but is absent in most normal cells. So, targeting telomere-maintenance mechanisms could potentially half tumour growth across a broad spectrum of tumour types, with little cytotoxic effect outside tumours. Here, we describe the current understanding of telomere biology, and the application of this knowledge to the development of anticancer drugs.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd793DOI Listing
May 2002
1 Read

Publication Analysis

Top Keywords

cancer cells
4
80% cancer
4
cytotoxic tumours
4
cells examined
4
examined absent
4
activated 80%
4
tumours describe
4
complex telomerase
4
current understanding
4
describe current
4
key factor
4
factor activated
4
absent normal
4
normal cells
4
spectrum tumour
4
half tumour
4
tumour growth
4
broad spectrum
4
growth broad
4
mechanisms half
4

References

(Supplied by CrossRef)

E Sahai et al.
Nature Rev. Cancer 2002

J Pines et al.
Nature Cell Biol. 1999

EH Blackburn et al.
Cell 2001

R McElligott et al.
EMBO J. 1997

KE Huffman et al.
J. Biol. Chem. 2000

WE Wright et al.
Genes Dev. 1997

B van Steensel et al.
Cell 1998

P Baumann et al.
Science 2001

TM Nakamura et al.
Science 1997

T Simonsson et al.
Biol. Chem. 2001

SM Kerwin et al.
Curr. Pharm. Des. 2000

Similar Publications